Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 9
Submit an article Journal homepage
239
Views
9
CrossRef citations to date
0
Altmetric
Letters to the Editor

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Kami MaddocksDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; Correspondence[email protected]
,
Erin HertleinDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Timothy L. ChenComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;
,
Amy J. WagnerComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;
,
Yonghua LingDivision of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA;
,
Joseph FlynnDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Mitch PhelpsDivision of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA;
,
Amy J. JohnsonDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
John C. ByrdDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; ;Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA
&
Jeffrey A. JonesDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
show all
Pages 2212-2215 | Received 06 Aug 2015, Accepted 02 Dec 2015, Published online: 14 Jan 2016

References

  • Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152:714–726.
  • Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–105.
  • Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44:47–52.
  • Goetz MP, Toft DO, Ames MM, et al. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol. 2003;14:1169–1176.
  • Hertlein E, Wagner AJ, Jones J, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010;116:45–53.
  • Lancet J, Gojo I, Baer M, et al. Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the Hsp-90 inhibitor, KOS-1022 (17-DMAG), in patients with refractory hematological malignancies. J Clin Oncol. 2006;24:2081.
  • Lancet JE, Gojo I, Burton M, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010;24:699–705.
  • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
  • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
  • Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–2294.
  • Graham B, Curry J, Smyth T, et al. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer. Cancer Sci. 2012;103:522–527.
  • Smyth T, Paraiso KH, Hearn K, et al. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther. 2014;13:2793–2804.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.